drugset / Trial / NCT03440021
Single-dose Novel Selective alpha2c Antagonist Pharmaco-MRI Study in Healthy Volunteers
Phase 1
Completed
68 enrolled
University of Cape Town
Orion Corporation, Orion Pharma · collabUniversity of Oxford · collab
RandomizedParallel-groupDouble-blindBasic science
Summary
The aim of the present study is to investigate changes in neural activity (BOLD signal), as measured using fMRI, in brain areas associated with emotional and working memory during task performance after single-dose administration of a novel selective alpha2c adrenoceptor antagonist (ORM-12741) in healthy volunteers. Further, it will be explored whether ORM-12741 affects connectivity between brain areas in rest, as measured using fMRI, and cognitive performance in the sample under investigation.
Timeline
- Start
- 2018-03-26
- Primary completion
- 2018-12-05
- Completion
- 2018-12-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ORM-12741 | Small molecule | 10 mg | — |
| Subject | ORM-12741 | Small molecule | 60 mg | — |
Indications
No indication recorded.